Evidence map›Paper›PMID 26202986›Full record

ArticleJournal of immunology (Baltimore, Md. : 1950)2015

γ-Tilmanocept, a New Radiopharmaceutical Tracer for Cancer Sentinel Lymph Nodes, Binds to the Mannose Receptor (CD206).

Abul K Azad, Murugesan V S Rajaram, Wendy L Metz, Frederick O Cope, Michael S Blue, David R Vera, Larry S Schlesinger

Registry-linked trialOpen access · bronzeAbstract read
In one paragraph

Article in Journal of immunology (Baltimore, Md. : 1950), 2015. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT04663126 (Pilot Study to Test the Feasibility of IV Injected Tc-99m-tilmanocept for Imaging of M2-like Tumour Associated Macrophages in Metastatic Melanoma), which is not on this map. Cited by 45 papers.

0numbers the graph read from it
0cells of the map it votes in
45citing papers in PubMed
3.5field-weighted citation impact, top 7% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

NCT04663126 early_phase1terminatednot on this mapstarted 2021, after this paper: background citation

Pilot Study to Test the Feasibility of IV Injected Tc-99m-tilmanocept for Imaging of M2-like Tumour Associated Macrophages in Metastatic Melanoma

TypeinterventionalSponsorJohn O. PriorRan2021 to 2023Enrolled5ConditionsMelanomaArmsTc-99m tilmanocept
3 · Its place in the literature

Who cites it

45 citing papers in PubMed, 87 citations in OpenAlex.

  1. Article
  2. Article
  3. The glymphatic system and glioblastoma.Brain : a journal of neurology · 2026
    Review
  4. Tracking macrophages by direct and indirectEuropean journal of nuclear medicine and molecular imaging · 2026
    Article
  5. Single Photon Emission Computed Tomography Tracer.Recent results in cancer research. Fortschritte der Krebsforschung. Progres dans les recherches sur le cancer · 2026
    Review
  6. Article
  7. Modulation of infiltrating CD206The European respiratory journal · 2025
    Article
  8. Article
  9. Utility of [Cancer immunology, immunotherapy : CII · 2025
    Article
  10. Article
  11. CD206Thorax · 2024
    Article
  12. Article
  13. Article
  14. Article
  15. Article
  16. Article
  17. A pilot study of lymphoscintigraphy with tracer injection into the human brain.Journal of cerebral blood flow and metabolism : official journal of the International Society of Cerebral Blood Flow and Metabolism · 2023
    Article
  18. Review
  19. Review
  20. Carbohydrate-based drugs launched during 2000Acta pharmaceutica Sinica. B · 2022
    Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors at 4 institutions in 1 country.

Abul K AzadCenter for Microbial Interface Biology, The Ohio State University, Columbus, OH 43210; Department of Microbial Infection and Immunity, The Ohio State University, Columbus, OH 43210;
Murugesan V S RajaramCenter for Microbial Interface Biology, The Ohio State University, Columbus, OH 43210; Department of Microbial Infection and Immunity, The Ohio State University, Columbus, OH 43210;
Wendy L MetzClinical and Medical Groups, Navidea Biopharmaceuticals, Inc., Dublin, OH 43017; and.
Frederick O CopeClinical and Medical Groups, Navidea Biopharmaceuticals, Inc., Dublin, OH 43017; and.
Michael S BlueClinical and Medical Groups, Navidea Biopharmaceuticals, Inc., Dublin, OH 43017; and.
David R VeraDepartment of Radiology, UC San Diego Moores Cancer Center, University of California, San Diego, La Jolla, CA 92093.
Larry S SchlesingerCenter for Microbial Interface Biology, The Ohio State University, Columbus, OH 43210; Department of Microbial Infection and Immunity, The Ohio State University, Columbus, OH 43210; larry.schlesinger@osumc.edu.
Navidea Biopharmaceuticals (United States) · USThe Ohio State University · USInterface (United States) · USUniversity of California, San Diego · US

Funding

TB and Innate Immune Regulation of Lung MacrophagesR01AI059639 · NIAID · OHIO STATE UNIVERSITY · PI SCHLESINGER, LARRY S. · 2005 to 2016
$3.2M
TB and Innate Immune Regulation of Lung MacrophagesR21AI059639 · NIAID · OHIO STATE UNIVERSITY · PI SCHLESINGER, LARRY S. · 2004 to 2004
$299k
NIAID NIH HHS AI059639NIAID NIH HHS R01 AI059639
6 · The paper itself

Abstract

γ-Tilmanocept ((99m)Tc-labeled-tilmanocept or [(99m)Tc]-tilmanocept) is the first mannose-containing, receptor-directed, radiolabeled tracer for the highly sensitive imaging of sentinel lymph nodes in solid tumor staging. To elucidate the mannose-binding receptor that retains tilmanocept in this microenvironment, human macrophages were used that have high expression of the C-type lectin mannose receptor (MR; CD206). Cy3-labeled tilmanocept exhibited high specificity binding to macrophages that was nearly abolished in competitive inhibition experiments. Furthermore, Cy3-tilmanocept binding was markedly reduced on macrophages deficient in the MR by small interfering RNA treatment and was increased on MR-transfected HEK 293 cells. Finally, confocal microscopy revealed colocalization of Cy3-tilmanocept with the macrophage membrane MR and binding of labeled tilmanocept to MR(+) cells (macrophages and/or dendritic cells) in human sentinel lymph node tissues. Together these data provide strong evidence that CD206 is a major binding receptor for γ-tilmanocept. Identification of CD206 as the γ-tilmanocept-binding receptor enables opportunities for designing receptor-targeted advanced imaging agents and therapeutics for cancer and other diseases.

Indexed as

CarbocyaninesCells, CulturedDextransFlow CytometryHEK293 CellsHumansImmunohistochemistryLectins, C-TypeLymph NodesMacrophagesMannansMannose-Binding LectinsMannose ReceptorMicroscopy, ConfocalMolecular StructureNeoplasmsCarbocyaninescyanine dye 3DextransLectins, C-TypeMannansMannose-Binding LectinsMannose ReceptorRadiopharmaceuticalsReceptors, Cell Surfacetechnetium-diethylenetriaminepentaacetic acid-mannosyl-dextranTechnetium Tc 99m Pentetate

Identifiers

PMID26202986
PMCPMC4543904
OpenAlexW1873664205

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.